燒傷疼痛：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

市場概覽

• 預計到 2035 年，德國燒傷疼痛治療市場將從 6,500 萬美元成長到 1.25 億美元，複合年成長率將達到 6-7%。
• 義大利的燒燙傷患者人數呈現穩定成長趨勢，儘管增幅較低（年均複合成長率約 1%）。

燒傷疼痛概述

燒傷疼痛是一種極為嚴重、複雜且動態的神經發炎性疾病，其特徵是組織破壞導致的強烈傷害性刺激和受損神經末梢產生的神經病變訊號同時存在。其病理生理機轉是由嚴重的發炎級聯反應觸發，導致周邊敏化（原發性痛覺過敏）和持續性中樞神經系統敏化（次發性痛覺過敏）。

臨床上，燒傷疼痛表現極為多樣，需要明確地分為以下幾類：

1. 背景疼痛（持續性、發炎性）

2. 突發性疼痛（陣發性加重）

3. 與手術相關的疼痛（創傷護理、清創、移植過程中的劇烈疼痛）

急性疼痛管理不足與長期併發症（包括慢性神經病變疼痛和創傷後壓力症候群 (PTSD)）密切相關，因此早期有效干預至關重要。

現代治療模式正從鴉片類藥物單一療法轉向包含以下方面的多面向鎮痛方法：

• 用於治療急性疼痛和手術相關疼痛的鴉片類藥物
• 非類固醇抗發炎藥和對乙醯胺酚用於抑制炎症
• 加巴噴丁類藥物用於調節神經病變疼痛
• NMDA 受體拮抗劑（如氯胺酮）用於治療嚴重疼痛，並具有減少鴉片類藥物用量的效果。

在高級燒傷治療中，以下技術正日益整合應用：

• 局部麻醉
• α2促效劑用於鎮靜和緩解焦慮（例如，Dexmedetomidine）
• 非藥物療法，例如基於虛擬實境（VR）的分心療法，旨在應對心理負擔。

這種多方面、以患者為中心的治療方法體現了需要同時管理燒傷疼痛的生理和心理層面。

主要亮點

• 燒傷疼痛是一個高強度、以治療主導的治療領域，治療需求與發病率的關係比與盛行率的關係更為密切。
• 義大利每年燒傷病例數預計將緩慢成長（年複合成長率為 1%），從 188,000 例增加至 204,000 例，反映出疾病負擔穩定但持續存在。

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於微軟Excel）
• 流行病學數據（MS Excel，互動式工具）
• 高階主管洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 我們如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物核准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

大公司

• Shanghai Bao Pharmaceuticals Co.

目錄

第1章：主要調查結果和分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章：疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

• 重點
• 發病率/盛行率
• 已確診並接受藥物治療的患者人數
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 按藥物分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
  • 重點
  • 診斷和治療過程/演算法
  • 主要治療方法概述及KOL洞察
• 新興治療方法
  • 重點
  • 值得關注的後期新治療方法－概述、市場上市預期及KOL洞察
  • 值得關注的早期管道

第6章：未滿足的需求與TPP分析

• 主要未滿足的需求以及透過新興治療方法實現的未來可能性
• TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

Burn Pain Market Outlook

Thelansis's "Burn Pain Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Burn Pain treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Burn Pain Overview

Burn pain is a uniquely severe, complex, and dynamic neuroinflammatory condition characterized by the coexistence of intense nociceptive input from tissue destruction and neuropathic signaling from damaged nerve endings. The pathophysiology is driven by profound inflammatory cascades, resulting in peripheral sensitization (primary hyperalgesia) and sustained central nervous system sensitization (secondary hyperalgesia).

Clinically, burn pain is highly heterogeneous and requires clear stratification into:

1. Background pain (persistent, inflammatory)

2. Breakthrough pain (episodic exacerbations)

3. Procedural pain (severe pain during wound care, debridement, and grafting)

Inadequate acute pain control is strongly associated with long-term complications, including chronic neuropathic pain and post-traumatic stress disorder (PTSD), making early and effective intervention critical.

The modern treatment paradigm has shifted away from opioid monotherapy toward a multimodal analgesic approach, incorporating:

• Opioids for acute and procedural pain
• NSAIDs and acetaminophen for inflammatory control
• Gabapentinoids for neuropathic modulation
• NMDA receptor antagonists (e.g., ketamine) for severe pain and opioid-sparing effects

Advanced burn care increasingly integrates:

• Regional anesthesia techniques
• Alpha-2 agonists (e.g., dexmedetomidine) for sedation and anxiolysis
• Non-pharmacological interventions, such as virtual reality (VR)-based distraction therapy, to address psychological burden

This multimodal, patient-centric approach reflects the need to manage both the physiological and psychological dimensions of burn pain.

Key Highlights

• Burn pain represents a high-intensity, procedure-driven therapeutic area, where treatment demand is closely linked to incidence rather than prevalence.
• In Italy, the annual burn incidence population is expected to grow modestly (1% CAGR), increasing from 188K to 204K cases, reflecting stable but persistent disease burden.

Market Overview

• The burn pain market in Germany is projected to grow from $65M to $125M by 2035, reflecting a robust CAGR of 6-7%
• The burn patient population shows low but steady growth (~1% CAGR) in Italy

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard/report will cost USD 1,750 per country

Companies Mentioned

• Shanghai Bao Pharmaceuticals Co.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)